Acumen Pharmaceuticals In...

0.99
-0.09 (-8.33%)
At close: Apr 03, 2025, 2:14 PM

Acumen Pharmaceuticals Statistics

Share Statistics

Acumen Pharmaceuticals has 60.57M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding 60.57M
Shares Change (YoY) 0%
Shares Change (QoQ) 0%
Owned by Institutions (%) 70.73%
Shares Floating 44.28M
Failed to Deliver (FTD) Shares 2.44K
FTD / Avg. Volume 0.94%

Short Selling Information

The latest short interest is 1.83M, so 3.04% of the outstanding shares have been sold short.

Short Interest 1.83M
Short % of Shares Out 3.04%
Short % of Float 4.17%
Short Ratio (days to cover) 4.48

Valuation Ratios

The PE ratio is -1.01 and the forward PE ratio is -1.05. Acumen Pharmaceuticals's PEG ratio is -0.02.

PE Ratio -1.01
Forward PE -1.05
PS Ratio 0
Forward PS 1.2
PB Ratio 0.57
P/FCF Ratio -1.2
PEG Ratio -0.02
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Acumen Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.16.

Current Ratio 6.46
Quick Ratio 6.46
Debt / Equity 0.16
Debt / EBITDA -0.29
Debt / FCF -0.33
Interest Coverage -28.03

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1.68M
Employee Count 61
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -72.63% in the last 52 weeks. The beta is 0.02, so Acumen Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.02
52-Week Price Change -72.63%
50-Day Moving Average 1.35
200-Day Moving Average 2.19
Relative Strength Index (RSI) 34.7
Average Volume (20 Days) 257.91K

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -114.02M
Net Income -102.33M
EBITDA -98.08M
EBIT -98.26M
Earnings Per Share (EPS) -1.71
Full Income Statement

Balance Sheet

The company has 35.63M in cash and 28.73M in debt, giving a net cash position of 6.89M.

Cash & Cash Equivalents 35.63M
Total Debt 28.73M
Net Cash 6.89M
Retained Earnings -325.13M
Total Assets 238.99M
Working Capital 150.7M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -86.22M and capital expenditures -16K, giving a free cash flow of -86.23M.

Operating Cash Flow -86.22M
Capital Expenditures -16K
Free Cash Flow -86.23M
FCF Per Share -1.44
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

ABOS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ABOS is $7, which is 554.2% higher than the current price. The consensus rating is "Buy".

Price Target $7
Price Target Difference 554.2%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Scores

Altman Z-Score -1.83
Piotroski F-Score 2